{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:26:30Z","timestamp":1792686390327,"version":"4.5.0"},"reference-count":33,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,12,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Selinexor is an oral inhibitor of the nuclear export protein exportin 1. Preclinical studies demonstrated synergistic antimyeloma activity between selinexor and proteasome inhibitors (PI) through suppression of NF-\u03baB signaling and nuclear retention of tumor suppressor proteins. We tested selinexor in combination with low-dose bortezomib and dexamethasone (SVd) for the treatment of relapsed or refractory multiple myeloma (MM). The primary objectives of this study were to determine the safety profile, overall response rate (ORR), and a recommended phase 2 dose (RP2D) of SVd. We enrolled 42 patients to receive selinexor (60, 80, or 100 mg orally) plus bortezomib (1.3 mg\/m2 subcutaneously) and dexamethasone (20 mg orally) once or twice weekly in 21- or 35-day cycles. Patients had a median of 3 (range 1-11) prior lines of therapy, and 50% were refractory to a PI. Treatment-related grade 3 or 4 adverse events reported in \u226510% of patients were thrombocytopenia (45%), neutropenia (24%), fatigue (14%), and anemia (12%). Incidence (4 patients, 10%) and grade (\u22642) of peripheral neuropathy were low. The ORR for the entire population was 63%: 84% ORR for PI nonrefractory and 43% for PI-refractory patients. The median progression-free survival for all patients was 9.0 months; 17.8 months for PI nonrefractory, and 6.1 months for PI refractory. SVd treatment produced high response rates in patients with relapsed or refractory MM, including borezomib-refractory MM, with no unexpected side effects. The RP2D is selinexor (100 mg once weekly), bortezomib (1.3 mg\/m2 once weekly for 4 weeks), and dexamethasone (40 mg once weekly) per 35-day cycle. This trial was registered at www.clinicaltrials.gov as #NCT02343042.<\/jats:p>","DOI":"10.1182\/blood-2018-06-858852","type":"journal-article","created":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T18:33:02Z","timestamp":1540319582000},"page":"2546-2554","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":125,"title":["Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma"],"prefix":"10.1182","volume":"132","author":[{"given":"Nizar J.","family":"Bahlis","sequence":"first","affiliation":[{"name":"Charbonneau Cancer Research Institute, Calgary, AB, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Sutherland","sequence":"first","affiliation":[{"name":"Vancouver General Hospital, Vancouver, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrell","family":"White","sequence":"first","affiliation":[{"name":"QEII Health Sciences Center, Dalhousie University, Halifax, NS, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sebag","sequence":"first","affiliation":[{"name":"Royal Victoria Hospital, Montreal, QC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Lentzsch","sequence":"first","affiliation":[{"name":"Multiple Myeloma and Amyloidosis Service, Columbia University, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Kotb","sequence":"first","affiliation":[{"name":"Cancer Centre Manitoba, Winnipeg, MB, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Venner","sequence":"first","affiliation":[{"name":"Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gasparetto","sequence":"first","affiliation":[{"name":"Duke University Cancer Center, Durham, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Del Col","sequence":"first","affiliation":[{"name":"Myeloma Canada, Dorval, QC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Neri","sequence":"first","affiliation":[{"name":"Charbonneau Cancer Research Institute, Calgary, AB, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Reece","sequence":"first","affiliation":[{"name":"Princess Margaret Cancer Center, Toronto, ON, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kauffman","sequence":"first","affiliation":[{"name":"Karyopharm Therapeutics Inc, Newton, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Shacham","sequence":"first","affiliation":[{"name":"Karyopharm Therapeutics Inc, Newton, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. J.","family":"Unger","sequence":"first","affiliation":[{"name":"Karyopharm Therapeutics Inc, Newton, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Jeha","sequence":"first","affiliation":[{"name":"Karyopharm Therapeutics Inc, Newton, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Richard","family":"Saint-Martin","sequence":"first","affiliation":[{"name":"Karyopharm Therapeutics Inc, Newton, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jatin","family":"Shah","sequence":"first","affiliation":[{"name":"Karyopharm Therapeutics Inc, Newton, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Chen","sequence":"first","affiliation":[{"name":"Princess Margaret Cancer Center, Toronto, ON, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2020071008495744500_B1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrclinonc.2014.200","article-title":"Current treatment landscape for relapsed and\/or refractory multiple myeloma","volume":"12","author":"Dimopoulos","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2020071008495744500_B2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"issue":"11","key":"2020071008495744500_B3","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/leu.2009.147","article-title":"Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"issue":"10","key":"2020071008495744500_B4","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"issue":"11","key":"2020071008495744500_B5","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol"},{"issue":"8","key":"2020071008495744500_B6","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"2020071008495744500_B7","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"2020071008495744500_B8","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1016\/S2352-3026(16)30147-8","article-title":"Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial","volume":"3","author":"San-Miguel","year":"2016","journal-title":"Lancet Haematol"},{"issue":"20","key":"2020071008495744500_B9","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1182\/blood-2015-05-643320","article-title":"Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma","volume":"126","author":"Shah","year":"2015","journal-title":"Blood"},{"issue":"21","key":"2020071008495744500_B10","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2015-11-682518","article-title":"Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma","volume":"127","author":"Baz","year":"2016","journal-title":"Blood"},{"issue":"14","key":"2020071008495744500_B11","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"issue":"10068","key":"2020071008495744500_B12","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"2020071008495744500_B13","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1038\/bcj.2016.31","article-title":"A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma","volume":"6","author":"Becker","year":"2016","journal-title":"Blood Cancer J"},{"issue":"5","key":"2020071008495744500_B14","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1158\/2159-8290.CD-13-1005","article-title":"Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy","volume":"4","author":"Tan","year":"2014","journal-title":"Cancer Discov"},{"issue":"1","key":"2020071008495744500_B15","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/imr.12240","article-title":"The eukaryotic translation initiation factor eIF4E in the nucleus: taking the road less traveled","volume":"263","author":"Osborne","year":"2015","journal-title":"Immunol Rev"},{"issue":"2","key":"2020071008495744500_B16","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.celrep.2012.07.007","article-title":"The oncogene eIF4E reprograms the nuclear pore complex to promote mRNA export and oncogenic transformation","volume":"2","author":"Culjkovic-Kraljacic","year":"2012","journal-title":"Cell Reports"},{"issue":"12","key":"2020071008495744500_B17","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1038\/leu.2013.172","article-title":"Genome-wide studies in multiple myeloma identify XPO1\/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276","volume":"27","author":"Schmidt","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"2020071008495744500_B18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/leu.2013.115","article-title":"CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications","volume":"28","author":"Tai","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"2020071008495744500_B19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-014-0085-1","article-title":"Nucleo-cytoplasmic transport as a therapeutic target of cancer","volume":"7","author":"Gravina","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"48","key":"2020071008495744500_B20","doi-asserted-by":"crossref","first-page":"78883","DOI":"10.18632\/oncotarget.12428","article-title":"Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-\u03baB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death","volume":"7","author":"Kashyap","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"2020071008495744500_B21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-016-0304-z","article-title":"Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors","volume":"9","author":"Turner","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"21","key":"2020071008495744500_B22","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.3165.3165","article-title":"XPO1 inhibition disrupts ribosomal subunits assembly and induces multiple myeloma (MM) cell death [abstract]","volume":"122","author":"Tagoug","year":"2013","journal-title":"Blood"},{"issue":"48","key":"2020071008495744500_B23","doi-asserted-by":"crossref","first-page":"78896","DOI":"10.18632\/oncotarget.12969","article-title":"XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of I\u03baB\u03b1 and overcomes acquired proteasome inhibitor resistance in human multiple myeloma","volume":"7","author":"Turner","year":"2016","journal-title":"Oncotarget"},{"issue":"8","key":"2020071008495744500_B24","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2017-08-797886","article-title":"Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia","volume":"131","author":"Chen","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2020071008495744500_B25","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.2017.75.5207","article-title":"Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma","volume":"36","author":"Vogl","year":"2018","journal-title":"J Clin Oncol"},{"key":"2020071008495744500_B26","first-page":"1861","article-title":"A phase Ib\/II trial of selinexor combined with lenalidomide and low dose dexamethasone in patients with relapsed \/ refractory multiple myeloma [abstract]","volume":"130","author":"White","year":"2017","journal-title":"Blood"},{"key":"2020071008495744500_B27","first-page":"3136","article-title":"Selinexor in combination with pomalidomide and low dose dexamethasone in a relapsed \/ refractory multiple myeloma patient population with prior proteasome inhibitor and lenalidomide exposure [abstract]","volume":"130","author":"Chen","year":"2017","journal-title":"Blood"},{"key":"2020071008495744500_B28","first-page":"3100","article-title":"A phase 1b study to assess the combination of selinexor and daratumumab in patients with relapsed \/ refractory multiple myeloma previously exposed to proteasome inhibitor (PI) and immunomodulatory drugs (IMiDs) [abstract]","volume":"130","author":"Gasparetto","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2020071008495744500_B29","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"2020071008495744500_B30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study [published correction appears in Leukemia. 2012;26(5):1153]","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"issue":"5","key":"2020071008495744500_B31","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.clml.2014.03.005","article-title":"Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma","volume":"14","author":"Knopf","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"22","key":"2020071008495744500_B32","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/blood-2017-06-788323","article-title":"Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"key":"2020071008495744500_B33","first-page":"2097","author":"Driessen"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/132\/24\/2546\/1746874\/blood858852.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/132\/24\/2546\/1746874\/blood858852.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T12:50:24Z","timestamp":1594385424000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/132\/24\/2546\/39526\/Selinexor-plus-lowdose-bortezomib-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,13]]},"references-count":33,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2018,12,13]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2018-06-858852","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,13]]}}}